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Abstract
Abiraterone blocks androgen synthesis and prolongs survival in castration-resistant prostate 
cancer, which is otherwise driven by intratumoral androgen synthesis1,2. Abiraterone is 
metabolized in patients to D4A, which has even greater anti-tumor activity and structural 
similarities to endogenous steroidal 5α-reductase substrates, such as testosterone3. Here, we show 
that D4A is converted to at least 3 5α-reduced and 3 5β-reduced metabolites. The initial 5α-
reduced metabolite, 3-keto-5α-abi, is more abundant than D4A in patients with prostate cancer 
taking abiraterone, and is an androgen receptor (AR) agonist, which promotes prostate cancer 
progression. In a clinical trial of abiraterone alone, followed by abiraterone plus dutasteride (a 5α-
reductase inhibitor), 3-keto-5α-abi and downstream metabolites are depleted, while D4A 
concentrations rise, effectively blocking production of a tumor-promoting metabolite and 
permitting D4A accumulation. Furthermore, dutasteride does not deplete three 5β-reduced 
metabolites, which were also clinically detectable, demonstrating the specific biochemical effects 
of pharmacologic 5α-reductase inhibition on abiraterone metabolism. Our findings suggest a 
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previously unappreciated and biochemically specific method of clinically fine-tuning abiraterone 
metabolism to optimize therapy.
Metastatic prostate cancer generally responds initially to medical or surgical castration, 
followed by eventual resistance as castration-resistant prostate cancer (CRPC), which is 
driven by the metabolic capability of tumors to reconstitute potent androgens, mainly from 
dehydroepiandrosterone (DHEA)/DHEA-sulfate, and in turn stimulate the androgen receptor 
(AR)1,4,5. Abiraterone (Abi; administered orally as Abi acetate), a steroidal drug, inhibits 
17α-hydroxylase/17,20-lyase (CYP17A1), blocks androgen synthesis and prolongs survival, 
even after treatment with docetaxel chemotherapy6,7. Unfortunately, disease progression 
occurs and ultimately results in tumor lethality.
Abi is converted in patients by 3β-hydroxysteroid dehydrogenase (3βHSD) to Δ4-
abiraterone (D4A), which blocks multiple enzymes required for 5α-dihydrotestosterone 
(DHT) synthesis, directly and potently antagonizes the AR, and has more potent anti-tumor 
activity than abiraterone itself3. However, there is no known method to increase 
accumulation of D4A as an Abi metabolite and it is not known if there are other Abi 
metabolites that harbor clinically relevant biochemical activity that contribute to response or 
resistance to treatment with Abi.
The Δ4, 3-keto structure of D4A makes it potentially susceptible to 5α-reduction to 3-
keto-5α-Abi (5α-Abi) or 5β-reduction to 3-keto-5β-abi (5β-Abi), which are both 
irreversible reactions (Fig. 1a). 3-keto-reduction of both of these metabolites may reversibly 
convert them to their 3α-OH and 3β-OH congeners, making a total of 6 novel metabolites 
downstream of D4A (Fig. 1a and Extended Data Fig. 1). Conversion from Abi and D4A to 
all 3 5α-reduced metabolites, interconversion among the 3 5α-reduced metabolites, and 
interconversion among the 3 5β-reduced metabolites are detectable in the LAPC4, C4-2 and 
VCaP prostate cancer cell lines by mass spectrometry (Fig. 1b and Extended Data Fig. 2). In 
the LNCaP and LAPC4 human prostate cancer cell lines using an alternative method of 
detection (HPLC with UV absorption), direct incubations with D4A result in conversion to 
5α-Abi and 3α-OH-5α-Abi (Extended Data Fig. 3a and d) and treatment with 5α-Abi yields 
conversion to 3α-OH-5α-Abi (Extended Data Fig. 3b). Particularly in LAPC4, the 
reversibility of this reaction is demonstrable by 5α-Abi detection upon 3α-OH-5α-Abi 
treatment (Extended Data Fig. 3c); however, it appears that reduction to 3α-OH-5α-Abi 
appears to be the preferred directionality. Similarly, in vivo, 5α-Abi is preferentially 
converted to 3α-OH-5α-Abi, although the reverse reaction is also detectable (Fig. 1c). 3β-
OH-5α-Abi is also oxidized to 5α-Abi and converted to 3α-OH-5α-Abi. Reflecting the 
irreversible nature of steroid 5α-reduction, no Abi, D4A, or 5β-reduced metabolites are 
detectable after treatment with any of the 5α-reduced Abi metabolites. Furthermore, all 6 
metabolites are clinically detectable in the sera of 12 patients with CRPC undergoing 
treatment with Abi acetate (Fig. 1d; Extended Data Fig. 4 and Extended Data Table 1). 
Together, these data support a model in which once D4A is 5α-reduced to 5α-Abi, 3-keto 
reduction to both 3-(α and β)-OH isomers and the reverse reactions occur, both in prostate 
cancer cells and in vivo.
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Steroid 5α-reduction preserves the steroid planar structure and plays an essential role in the 
regulation of biologically active androgens (i.e., conversion of testosterone to DHT and Δ4-
androstenedione [AD] to 5α-androstanedione [5α-dione])8,9. On the other hand, steroid 5β-
reduction disrupts the planar conformation by introducing a 90° bend, which generally 
inactivates steroid hormones and facilitates clearance. We therefore focused subsequent 
studies on the pathway and metabolites of D4A 5α-reduction. 5α-Abi and 3α-OH-5α-Abi 
synthesis is facilitated via upstream conversion of Abi to D4A by 3βHSD (Extended Data 
Fig. 5a). In cells without endogenous steroid-5α-reductase (SRD5A) expression, conversion 
of D4A to 5α-Abi is enabled by expression of either SRD5A1 or SRD5A2 (Extended Data 
Fig. 5b). In LAPC4 cells, which predominantly express SRD5A18, genetically silencing 
SRD5A1 (Extended Data Fig. 5c) or pharmacologic blockade with the SRD5A1 inhibitor 
LY19170410, or clinically achievable concentrations of the dual isoenzyme inhibitor 
dutasteride11, blocks conversion of D4A to 5α-Abi and 3α-OH-5α-Abi (Extended Data Fig. 
5d). The aldo-keto reductase isoenzyme AKR1C2 is thought to be the predominant 3-keto 
reductase that converts the 3-keto steroid, DHT, to 5α-androstane-3α,17β-diol12. We found 
that AKR1C2 expression also enables the reduction of 5α-Abi to 3α-OH-5α-Abi (Extended 
Data Fig. 5e).
Next, we sought to determine the activities of 5α-reduced Abi metabolites on the androgen 
pathway. 5α-reduction of D4A to 5α-Abi and 3α-OH-5α-Abi is accompanied by 
attenuation or loss of CYP17A1, 3βHSD and SRD5A inhibition activity (Fig. 2a–c), as 
assessed by conversion from [3H]-pregnenolone to DHEA, [3H]-DHEA to AD, and [3H]-AD 
to 5α-dione, respectively. The effects, or lack thereof, for D4A and 5α-Abi metabolites on 
3βHSD, are consistent with observations of others that endogenous Δ4, 3-keto-steroids 
inhibit 3βHSD and that 5α-reduction leads to loss of inhibitory activity13.
The affinity of 5α-Abi is comparable to that of D4A for the T877A mutant AR in LNCaP 
and wild-type AR in LAPC4, whereas the affinities of 3α-OH-5α-Abi and Abi are lower 
(Fig. 2d). To assess the consequences of 5α-Abi binding to AR, expression of androgen-
responsive genes was assessed. Treatment with 5α-Abi results in expression of androgen-
responsive genes in LAPC4 and LNCaP (Fig. 2e–g). A lower level of induction occurs with 
3α-OH-5α-Abi treatment. The delayed and modest effect of 3α-OH-5α-Abi on induction of 
PSA is consistent with low binding affinity for AR and modest conversion of 3α-OH-5α-
Abi to 5α-Abi that appears to occur to a greater extent in LAPC4 compared with LNCaP 
(Extended Data Fig. 3c). Using a cDNA microarray and Gene Set Enrichment Analysis we 
found that 5α-Abi stimulates AR signature genes14 (Extended Data Fig. 6a–b) and that 81% 
of genes regulated by 5α-Abi are also regulated by DHT (Extended Data Fig. 6c–d and 
Extended Data Table 2). To test the effect of AR stimulation by 5α-Abi on tumor growth, 
CRPC xenografts were treated with 5α-Abi and 3α-OH-5α-Abi. 5α-Abi significantly 
shortened progression-free survival (P < 0.01), whereas 3α-OH-5α-Abi had no detectable 
effect when compared to control xenografts (Fig. 2h). We also tested all 3 5β-reduced Abi 
metabolites for effects on androgen-responsive gene expression and confirmed that 
perturbation of the steroid planar structure is accompanied by the absence of metabolite 
activity (Fig. 2i).
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We hypothesized that under conditions of Abi treatment, prostate cancer cells might develop 
the capacity to augment the conversion of D4A → 5α-Abi by SRD5A up-regulation. VCaP 
and LNCaP cells were cultured for 6 months with D4A or Abi, along with DHEA, to mimic 
the human adrenal androgen milieu (Fig. 3a). Cells propagated in long-term culture with 
D4A and Abi exhibited increased SRD5A enzyme activity, as assessed by conversion of 
[3H]-AD → 5α-reduced androgens, [3H]-T → DHT, and D4A → 5α-reduced Abi 
metabolites (Fig. 3b–c). Increased SRD5A enzyme activity was accompanied by a 
predominant increase in SRD5A1 mRNA (Extended Data Fig. 7a) and protein expression 
(Fig. 3d–e). The increase in SRD5A occurring with Abi or D4A treatment does not occur 
with enzalutamide treatment (Extended Data Fig. 7b–c). There was no change in AR-V7 
with Abi or D4A treatment (Extended Data Fig. 7d). Together, these results suggest that 
there is probably a selective growth advantage for depleting the anti-tumor activity 
associated with D4A and/or increasing the AR agonist activity of increased 5α-Abi 
concentrations.
Next, we hypothesized that the increased ratio of 5α-Abi:D4A of approximately 2.5:1 is 
specifically and clinically reversible by dual SRD5A isoenzyme inhibition with dutasteride 
in patients on treatment with Abi acetate. A phase II clinical trial (NCT01393730) of Abi 
acetate (1000 mg daily) plus prednisone (5 mg daily) for 2 months (2 cycles), followed by 
the addition of dutasteride at the start of cycle 3 (3.5 mg once daily; Fig. 4a) is ongoing in 
men with metastatic CRPC. Sixteen patients who had blood collected on Abi acetate alone 
(start of cycle 3) and after the addition of dutasteride (start of cycles 4 and 7) were included 
in the analysis. Strikingly, there was an 89% decline in the mean concentration of 5α-Abi 
after the addition of dutasteride (cycle 3: 25.8 nM vs. cycle 4: 2.9 nM; Fig. 4d). The other 
two 5α-reduced metabolites downstream of SRD5A exhibited similar declines (92% decline 
in 3α-OH-5α-Abi and 73% decline in 3β-OH-5α-Abi), further corroborating the effects of 
dutasteride on blocking 5α-reduction of D4A in patients. Pharmacologic SRD5A inhibition 
nearly doubled the mean serum concentration of D4A (cycle 3: 9.9 nM vs. cycle 4: 18.2 nM; 
Fig. 4c). Unexpectedly, the addition of dutasteride also nearly doubled the mean 
concentration of Abi (cycle 3: 191.2 nM vs. cycle 4: 372.4 nM; Fig. 4b), although this 
difference did not reach statistical significance (P = 0.051). Concentrations of Abi, D4A and 
5α-Abi metabolites at cycle 7, the second time point after addition of dutasteride, were 
similar to cycle 4, although the changes from Abi alone at baseline were slightly lessened 
(Fig. 4 and Extended Data Table 3). Finally, and in sharp contrast to the substantial decline 
in 5α-Abi metabolites after the addition of dutasteride, there was no decrease in any of the 3 
5β-reduced Abi metabolites, supporting a very specific biochemical effect of SRD5A 
inhibition on 5α-Abi metabolism (Fig. 4e). Together, these findings demonstrate that the 
elevated ratio of 5α-Abi:D4A is pharmacologically, specifically and clinically reversible 
with dutasteride.
CYP17A1 inhibition by Abi is clinically incomplete, as has been demonstrated by residual 
urinary androgen metabolites15 and high residual serum concentrations of DHEA-sulfate, 
the major androgen produced from the human adrenal16, which together persist in patients 
on Abi treatment. Molecular aberrations that sustain AR signaling partake in the 
development of CRPC17 and also drive Abi resistance18,19. Together, these studies suggest 
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that reversal of sustained AR signaling should have a therapeutic benefit in at least a subset 
of patients with Abi resistant disease.
A component of sustained AR signaling occurs by way of a continuous supply of 
endogenous androgens (testosterone and/or DHT) provided by maintained steroidogenesis. 
Preclinical models indeed suggest that Abi resistance can be driven by an up-regulation of 
steroidogenic enzymes20. Our findings demonstrate that along with providing potent 
endogenous androgens, steroidogenic enzymes may serve a dual purpose by also regulating 
Abi metabolism, specifically by hastening the elimination of the anti-tumor activity 
associated with D4A3 by converting it with increased SRD5A enzyme activity to 5α-Abi, 
which instead has tumor-promoting AR agonist activity. Consistent with our findings, 
SRD5A has been noted by others as one of the most up-regulated steroidogenic-enzyme 
transcripts in another model of Abi resistance20.
The coordinate effects of steroidogenic enzymes on endogenous steroids vs. Abi should be 
considered in view of our findings on extensive steroidogenic metabolism of Abi. For 
example, increased SRD5A enzyme activity should have concordant favorable effects on 
tumor growth by increasing DHT synthesis and converting D4A to 5α-Abi. On the other 
hand, increasing 3βHSD activity would be expected to have discordant effects, as it is 
required for synthesis of T and DHT (beneficial to tumor) but increases conversion of Abi to 
D4A (detrimental to tumor). In this context, the likelihood is that the net effect of increased 
intratumoral 3βHSD activity is probably beneficial, because the endogenous substrates (i.e., 
DHEA, Δ5-androstenediol and pregnenolone) are probably preferred over D4A. A third 
enzymatic reaction that is relevant both to endogenous 5α-reduced androgens and 5α-Abi is 
3α-OH-oxidation to 3-keto-steroids. Oxidation or ‘back conversion’ of (3α-OH) 5α-
androstanediol, which does not stimulate AR, to (3-keto) DHT, can stimulate AR 
signaling21,22. The net effect of this reaction on androgens and Abi metabolism is therefore 
expected to be concordant and stimulatory because in addition to increasing DHT synthesis, 
conversion of 3α-OH-5α-Abi to 5α-Abi also increases affinity for AR (Fig. 2d), stimulates 
androgen-responsive gene expression (Fig. 2e–g) and tumor growth (Fig. 2h).
Notwithstanding these considerations, the majority of Abi metabolites found in serum likely 
form independent of tumor metabolism and result from the activity of hepatic enzymes. 
Although we found that prostate cancer cell lines readily 5α-reduce D4A, no prostate 
cancer-dependent 5β-reduction was observed. Both steroid 5α- and 5β-reductase reactions 
are abundant in the liver. The contributions to treatment response of D4A depletion by 
intrinsic tumor SRD5A versus extrinsic metabolism remain to be determined. Nonetheless, 
in our clinical study adding dutasteride to treatment with Abi acetate, resulted in an 
approximately 90% decline in circulating concentrations of 5α-Abi, the immediate product 
of D4A 5α-reduction, with similar declines in the other 5α-Abi metabolites. D4A 
concentrations concomitantly rose after the addition of dutasteride, supporting the specific 
pharmacologic effect of dutasteride on D4A metabolism. Numerically, there was also a rise 
in Abi concentrations, and although this change did not reach the generally accepted level of 
statistical significance (P = 0.051), it does raise the possibility that SRD5A provides an 
important mechanism of Abi clearance, at least in a subset of patients.
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The absence of any effect on 5β-reduced Abi metabolites demonstrates the remarkable 
specificity of dutasteride on 5α-reduction of D4A. The presence and maintenance of 5β-
reduced metabolites further suggests an “escape” mechanism of metabolism with 
pharmacologic 5α-reductase inhibition, raising the possibility that D4A, and perhaps Abi 
concentrations, might be further elevated with 5β-reductase inhibition, resulting in further 
therapeutic potentiation.
Our studies demonstrate a clear and specific biochemical effect of SRD5A inhibition on 
D4A metabolism in patients treated with Abi that would be expected to intensify the benefit 
of Abi therapy. The clinical benefit of fine-tuning Abi metabolism with SRD5A inhibition 
requires further investigation in randomized trials.
Methods
Cell lines, drugs and constructs
LNCaP, 293T and VCaP cells were purchased from the American Type Culture Collection 
(Manassas, VA) and maintained in RPMI-1640 (LNCaP) or DMEM (293T and VCaP) with 
10% FBS (Gemini bio-products). The LAPC4 cell line was kindly provided by Dr. Charles 
Sawyers (Memorial Sloan Kettering Cancer Center, New York, NY) and grown in Iscove’s 
Modified Dulbecco’s Medium with 10% FBS. Stable LAPC4 cell lines with SRD5A1 
knockdown were established as previously described8. Plasmid pcDNA3-c17 (a generous 
gift of Dr. Walter Miller, University of California, San Francisco, CA) was used to establish 
the 293 stable cell line expressing human CYP17A1 as described23. Cell lines were 
authenticated by DDC Medical (Fairfield, OH) and determined to be mycoplasma free with 
primers 5′-ACACCATGGGAGCTGGTAAT-3′ and 5′-
GTTCATCGACTTTCAGACCCAAGGCAT-3′. Dutasteride was purchased from Medkoo 
Biosciences (Chapel Hill, NC). Enzalutamide was obtained from Medivation (San Francisco, 
CA). The AKR1C2 expression plasmid was a generous gift of Dr. Trevor Penning 
(University of Pennsylvania, Philadelphia, PA). Enzalutamide resistant cells were cultured 
with DMSO, 1μM or 10μM enzalutamide for more than 6 months (LAPC4) or 10 weeks 
(VCaP) with presence of 10nM DHEA. Abi or D4A resistant cells were cultured as 
indicated in Fig. 3a.
HPLC
Cell Line Metabolism: 0.2 million/ml cells were seeded and incubated in 12-well plates for 
~24 h before incubation with the indicated drugs or a mixture of [3H]-labeled (~1,000,000 
cpm/well; PerkinElmer, Waltham, MA) and non-radioactive androgens (final concentration, 
100 nM) at 37°C. Collected medium was treated with β-glucuronidase (Helix pomatia; 
Sigma-Aldrich), extracted with ethyl acetate:isooctane (1:1), and concentrated under 
nitrogen gas as described previously24.
Xenograft Metabolism: 107 VCaP cells with Matrigel were injected subcutaneously into 
orchiectomized NSG mice with 5 mg, 90 day sustained-release DHEA pellets (Innovative 
Research of American, Sarasota, FL). ~1000 mm3 xenografts were harvested, minced, and 
cultured in DMEM with 10% FBS at 37°C with the indicated drugs. Aliquots of medium 
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were collected at the indicated times. Collected medium was processed for HPLC with the 
same protocol as medium from cell lines.
HPLC analysis was performed on a Waters 717 Plus HPLC or an Agilent 1260 HPLC. Dried 
samples were reconstituted in 50% methanol and separated on Kinetex 100 × 2.1 mm, 2.6 
μm particle size C18 reverse-phase column (Phenomenex, Torrance, CA) using a methanol/
water gradient at 30°C. The column effluent was analyzed using a 254 nm UV-visible 
detector or β-RAM model 3 in-line radioactivity detector (IN/US Systems, Inc.) using 
Liquiscint scintillation cocktail (National Diagnostics, Atlanta, GA). All HPLC studies were 
conducted in triplicate and repeated at least 3 times in independent experiments. Results are 
shown as mean ± SD.
Gene expression and immunoblotting
Cells were starved with phenol red-free and serum free-medium for at least 48 h before 
treatment with the indicated drugs and/or androgens. RNA extraction and cDNA synthesis 
were performed with the GenElute Mammalian Total RNA miniprep kit (Sigma-Aldrich) 
and iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA) respectively. Quantitative PCR 
(qPCR) analysis was conducted in triplicate in an ABI 7500 Real-Time PCR machine 
(Applied Biosystems) using iTaq Fast SYBR Green Supermix with ROX (Bio-Rad) and 
primers for TMPRSS2, PSA and RPLPO, as described previously 4. SYBR Premix Ex Taq 
II (Takara) was used for SRD5A1, SRD5A2 and AR v7 detection. Primers used for AR 
detection are 5′-TCTTGTCGTCTTCGGAAATGT-3′ and 5′-
AAGCCTCTCCTTCCTCCTGTA-3′ 25. Primers used for AR v7 detection are 5′-
CCATCTTGTCGTCTTCGGAAATGTTATGAAGC-3′ and 5′-
TTTGAATGAGGCAAGTCAGCCTTTCT-3′26. Accurate quantitation of each mRNA was 
achieved by normalizing the sample values to RPLPO and to vehicle-treated cells. 50 μg cell 
lysate was used for immunoblot with rabbit anti-SRD5A1 (Abnova) and mouse anti–β-actin 
(Sigma-Aldrich) antibodies.
Microarray study and analysis
LAPC4 cells were starved with phenol red-free and serum free-medium for at least 48 h 
before treatment with the indicated drugs and/or androgens, in biological triplicate. RNA 
was extracted with mirVana™ miRNA isolation kit (Life technologies). The genomics core 
of Cleveland Clinic generated cDNA and performed the microarray with HumanHT-12 v4 
Expression BeadChip and iScan (Illumina). Hybrid signals were analyzed with Illumina 
GenomeStudio Software 2011.1 and normalized by the vehicle control group. Regulated 
genes are defined as detection p <0.01, fold change (compared to Ctrl group) > 1.55 or <0.5. 
Heatmap was generated with HemI software27. The complete results are uploaded in NCBI 
GEO as GSE75387.
Normalized, log2 transformed data was used for subsequent GSVA carried out using R 
(http://www.R-project.org) and Bioconductor software28. The 2500 genes with the highest 
median absolute deviation were selected for analysis. Enrichment scores were calculated for 
the gene set C2 Collection (curated pathways) from the Molecular Signatures Database 
version 5.1 (MSigDB v5.1) using the Bioconductor package ‘GSVA’29. Gene sets with a 
Li et al. Page 7
Nature. Author manuscript; available in PMC 2016 November 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
minimum of 10 genes and a maximum of 1000 genes were included. Significance testing of 
enrichment scores was performed with a moderated t-statistic (FDR < 0.05) using the 
Bioconductor package ‘limma’. Separately, GSEA was used to correlate the 5α-Abi 
expression data with an androgen receptor selective gene set described elsewhere14. The 
GSEA enrichment plot was generated as described elsewhere30,31.
Mouse xenograft studies
Male NSG mice, 6 to 8 weeks of age were obtained from the Cleveland Clinic Biological 
Resources Unit facility. All mouse studies were conducted under a protocol approved by the 
Cleveland Clinic Institutional Animal Care and Use Committee. 107 VCaP cells were 
injected subcutaneously with matrigel. Once tumors reached 100 mm3 (length × width × 
height × 0.52), mice were surgically orchiectomized and arbitrarily assigned to vehicle 
(n=9), 5α-Abi (n=10), or 3α-OH-5α-Abi (n=9) treatment groups. Mice were injected 
intraperitoneally with 0.15 mL 5α-Abi and 3α-OH-5α-Abi (0.15 mmol/kg/d and 0.075 
mmol/kg/d, respectively, in 5% benzyl alcohol and 95% safflower oil solution) every day for 
up to 20 days. Control groups were administered 0.15 mL 5% benzyl alcohol and 95% 
safflower oil solution via intraperitoneal injection every day. Tumor volume was measured 
every other day, and time to increase in tumor volume by 30% was determined (2 sequential 
increases). Mice were sacrificed at treatment day 20. The significance of the difference 
between treatment groups was assessed by Kaplan-Meier survival analysis using a log-rank 
test in SigmaStat 3.5.
AR competition assay
Cells were starved with phenol red-free and serum free-medium for at least 48 h and then 
treated with [3H]-R1881 and the indicated concentrations of drugs for 30 min. Cells were 
washed thoroughly with PBS and then lysed with RIPA buffer. Intracellular radioactivity 
was measured with a Beckman Coulter LS60001C liquid scintillation counter and 
normalized to the protein concentration as detected with a Wallac Victor2 1420 Multilabel 
counter (Perkin Elmer).
Patient serum collection and drug extraction
Twelve patients with CRPC undergoing standard treatment with Abi acetate at Cleveland 
Clinic were consented under an Institutional Review Board – approved protocol (Case 
7813). Blood was collected using Vacutainer Plus serum blood collection tubes 
(#BD367814, Becton Dickenson, Franklin Lakes, NJ), between 1 and 16 hours after the 
1000mg daily dose of Abi acetate was administered, and allowed to clot. Tubes were 
centrifuged at 2500 RPM or 1430 x g for 10 minutes. Serum aliquots were frozen at -80°C 
until processing. To study the effect of dutasteride on Abi metabolism, serum samples were 
collected from patients treated on a phase II clinical trial at Dana-Farber Cancer Institute 
(NCT01393730). Each patient received Abi acetate (1,000 mg daily) plus prednisone (5 mg 
daily) for 2 cycles (8 weeks) and then additional treatment with dutasteride (3.5 mg daily) 
was initiated. Samples were collected on treatment with Abi alone and after addition of 
dutasteride (start of cycles 3, 4 and 7). Seventeen patients treated at this institution on this 
clinical trial had blood available from all 3 time points. One patient had Abi concentrations 
that were under the limit of detection and was later determine to have stopped treatment 
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because of adverse effects and was therefore not included in the analysis. Drug metabolites 
and internal standard (d4-abiraterone, Toronto Research Chemicals Inc, Ontario Canada) 
were extracted from 100 μL of patient serum with methyl tert-butyl ether (Sigma Aldrich, St. 
Louis, MO), evaporated under a stream of nitrogen gas and reconstituted in methanol:water 
(50:50) prior to mass spectrometry analysis. Standard curves were generated using human 
serum spiked with known concentrations of each metabolite to enable determination of 
unknown concentrations in patient samples.
Mouse serum extraction
20 μl of mouse serum were precipitated with 500 μl methanol containing the internal 
standard (d4-abiraterone) the supernatant was then injected into the mass analyzer. Standard 
curves were prepared with mice serum spiked with known metabolites concentrations for 
accurate determination of unknown metabolites concentrations.
Cell line media extraction
200 μl media collected at different time points were extracted with methyl tert-butyl ether 
(Sigma Aldrich, St. Louis, MO), evaporated under a stream of nitrogen gas and reconstituted 
in methanol:water (50:50) prior to mass spectrometry analysis.
Mass spectrometry
Samples were analyzed on a ultra high-performance liquid chromatography station 
(Shimadzu, Kyoto, Japan) with a DGU-20A3R degasser, 2 LC-30AD pumps, a SIL-30AC 
autosampler, a CTO-10A column oven and a CBM-20A system controller in tandem with a 
QTRAP 5500 mass spectrometer (AB Sciex, Framingham, MA). Drug metabolites were 
ionized using electrospray ionization in positive ion mode. Multiple reaction monitoring was 
used to follow mass transitions for Abi, IS, and the metabolites (Table S1). Due to the 
similarity in structure and mass transitions for the metabolites it was necessary to separate 
them with chromatography. Separation of drug metabolites was achieved using a mobile 
phase consisting of LC-MS grade (Fisher) methanol: acetonitrile: water:formic acid 
(39:26:34:1) at a flow rate of 0.2 ml/min., and C18 analytical column; Zorbax Eclipse plus 
150 × 2.1 mm, 3.5μm (Agilent, Santa Clara, CA).
Chemical Synthesis
See supplemental methods.
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Extended Data
Extended Data Figure 1. 
Synthesis of abiraterone metabolites. (a) Synthesis of 5α-Abi, 3α-hydroxy-5α-Abi and 3β-
hydroxy-5α-Abi. (b) Synthesis of 5β-Abi, 3α-hydroxy-5β-Abi and 3β-hydroxy-5β-Abi. (c) 
Synthesis of D4A.
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Extended Data Figure 2. 
Genesis and interconversion of Abi metabolites in the (a) C4-2 and (b) VCaP prostate cancer 
cell lines. Cells were treated with Abi or the indicated metabolite (0.1 μM) for 24 or 48 
hours and each of the indicated metabolites was detected by LC-MS/MS in triplicate. Error 
bars represent the SD.
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Extended Data Figure 3. 
In vitro time course formation of 5α-reduced Abi metabolites. a–c, Conversion from D4A to 
5α-reduced Abi metabolites (a), 3-keto reduction of 5α-Abi to 3α-OH-5α-Abi (b), and 3α-
OH-oxidation of 3α-OH-5α-Abi to 5α-Abi (c) is detectable in LNCaP and LAPC4 prostate 
cancer cell lines. Cells were treated with 10 μM of the indicated compounds, metabolites 
were separated by high performance liquid chromatography (HPLC) and quantitated by UV 
spectroscopy. Experiments were performed in triplicate at least 3 times and error bars 
represent the SD. (d), Examples of HPLC and UV absorption tracings for incubations of 
prostate cancer cell lines with D4A, 5α-Abi and 3α-OH-5α-Abi.
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Extended Data Figure 4. 
Clinical presence of 5α-reduced and 5β-reduced Abi metabolites in patients treated with Abi 
acetate. a, Dot plot of Abi and its metabolites expressed as the percentage of the total of Abi 
and its metabolites. b, LC-MS/MS separation of Abi metabolite standards and an example 
from serum obtained from a patient on Abi treatment.
Extended Figure 5. 
Enzymes involved in the formation of 5α-reduced Abi metabolites. a, 3βHSD1 catalyzes the 
conversion of Abi to D4A and downstream accumulation of 5α-Abi and 3α-OH-5α-Abi. 
LAPC4 cells were transiently transfected with the indicated amount of an expression 
construct encoding 3βHSD1 or vector control before treatment with Abi. b, Conversion of 
D4A to 5α-Abi is catalyzed by SRD5A1 or SRD5A2. The indicated amounts of SRD5A1, 
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or SRD5A2, or empty vector plasmids were transfected into 293T cells, and cells were 
incubated with D4A for the designated incubation times. c, SRD5A1 silencing blocks 5α-
reduction of D4A. LAPC4 cells stably expressing shRNAs targeting SRD5A1 or 
nonsilencing control were treated with D4A and metabolites for the indicated times. d, 
Pharmacologic SRD5A inhibition blocks 5α-reduction of D4A. LAPC4 cells were treated 
with D4A and the SRD5A inhibitors dutasteride or LY191704. A parallel control experiment 
is shown with inhibition of 5α-reduction of [3H]-AD. e, Conversion of 5α-Abi to 3α-
OH-5α-Abi is catalyzed by AKR1C2. 293T cells were transfected with AKR1C2 or empty 
vector and treated with 5α-Abi for the indicated times. For all experiments, metabolites were 
separated by HPLC and quantitated by UV spectroscopy (Abi metabolites) or with a beta-
RAM ([3H]-androgens). Error bars represent SD in all experiments. All experiments were 
performed at least 3 times.
Extended Data Figure 6. 
Gene expression profile of stimulation by 5α-Abi and DHT. a. Unbiased pathway analysis of 
5α-abi regulated genes. b, Gene Set Enrichment Analysis of 5α-abi regulated genes with the 
AR signature gene set. c, Gene expression in LAPC4 cells stimulated by 1μM 5α-Abi or 
0.1nM DHT for 48h. Regulated genes were determined by detection p value <0.01, 
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upregulation >1.55 or downregulation <0.5 compared with vehicle control group. d, Venn 
diagram of 5α-abi and DHT regulated genes.
Extended Data Figure 7. 
Transcript expression regulation in the presence of Abi, D4A or Enz. a, SRD5A1 and 
SRD5A2 expression in VCaP cells treated with Abi or D4A as indicated in Figure 3. b, 
SRD5A1 and SRD5A2 expression does not change with Enz treatment. c, SRD5A1 protein 
abundance does not change with Enz treatment in LAPC4 or VCaP. d, AR-v7 expression is 
unchanged in LNCaP cells treated with Abi or D4A as indicated in Figure 3. Expression was 
normalized to RPLPO and vehicle treated cells for all comparisons. Errors bars represent the 
SD.
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Extended Data Table 1
Data for each of the 12 patients treated with Abi acetate.
Patient
Time 
from
last dose 
to
blood 
draw
Treatment
duration
(Month)
Abi(nM) D4A(nM) 5α-Abi (nM) 3α-OH-5α-Abi(nM)
3β-OH-5α-
Abi(nM) 5β-Abi (nM)
3α-OH-5β-
Abi(nM)
3β-OH-5β-Abi
(nM)
#1 2h 32 24.8 3.7 3.9 1.2 0.3 7.0 18.4 26.8
#2 3h 15min 3 611.3 20.7 82.0 8.5 2.8 129.9 48.2 99.5
#3 13h 20min 9 133.5 6.7 43.2 8.4 2.9 65.9 48.3 88.7
#4 2h 30min 26 138.8 3.7 30.6 3.3 1.5 17.1 9.8 19.5
#5 4h 16min 3 26.6 9.5 8.1 1.7 0.4 57.9 60.7 94.6
#6 11h 15min 4 197.0 15.4 43.1 9.3 3.2 49.2 53.0 70.7
#7 6h 20min 7 319.3 14.5 186.9 23.0 5.1 133.6 60.0 79.3
#8 3h 15min 4 6.3 0.8 1.7 0.6 0.2 2.6 9.0 4.3
#9 9h 20min 5 30.8 1.3 2.5 0.7 0.3 1.8 5.7 6.9
#10 8h 10min 4 47.8 8.0 10.4 2.5 1.0 53.3 74.3 79.9
#11 10h 40min 6 102.8 5.2 35.7 10.5 2.8 17.1 30.0 46.6
#12 2h 35 257.5 7.3 31.1 5.9 6.0 63.0 93.5 118.4
Extended Data Table 2
Genes regulated by 5α-abi.
SYMBOL 5α-Abi/Ctrl SYMBOL 5α-Abi/Ctrl SYMBOL 5α-Abi/Ctrl SYMBOL 5α-Abi/Ctrl
ABCA1 1.832 FLJ20021* 2.372 LOC440509* 1.558 SENP7* 1.672
ABCC4*† 2.173 FLJ27365 2.034 LOC441763* 1.838 SERHL* 1.613
ABCG1 2.314 FLJ41603* 1.842 LOC554208 1.643 SERHL2* 2.703
ACACB 1.677 FLJ42562* 1.850 LOC643376 2.246 SERPINE2* 2.836
ALDH4A1* 1.712 FOXC1* 1.618 LOC644096 1.760 SGCB* 2.219
ANKRD29* 2.336 FOXN4* 3.227 LOC644584 1.929 SGPP1* 1.580
ANKS3* 1.561 FOXQ1 1.590 LOC646434 1.733 SLAIN1 1.668
ARL15 1.674 FXYD3 1.631 LOC646783* 1.647 SLC16A9* 1.991
BCAR3 1.712 GAL3ST4 2.004 LOC647104* 1.954 SLC45A3*† 1.855
BEND5 1.605 GARNL3* 1.673 LOC651075* 1.754 SNORA58* 1.793
C10orf41 1.566 GDF15* 2.437 LOC728178 1.772 SORD* 1.649
C14orf159 1.831 GHR* 2.458 LOC729799* 1.677 ST3GAL6* 1.605
C1orf116*† 4.181 HDAC11 1.564 LPCAT4* 1.949 STXBP5 1.574
C1orf21*† 1.631 HES6* 1.779 MAFB* 2.184 TBC1D16* 1.597
C1orf74* 1.619 HMGCS2 1.562 MBOAT2 1.576 THAP3 1.811
C5orf41 1.634 HMOX2 1.619 MBP* 1.671 TINF2* 1.687
C6orf105* 1.697 HOMER2*† 2.191 MCOLN2 1.587 TMEM45B 2.023
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SYMBOL 5α-Abi/Ctrl SYMBOL 5α-Abi/Ctrl SYMBOL 5α-Abi/Ctrl SYMBOL 5α-Abi/Ctrl
C7orf38 1.767 HOXC8 1.650 MGC16384 1.886 TMPRSS2*† 1.730
CA12*† 1.821 HS6ST1* 1.671 MIR1974* 1.566 TRIM36* 2.045
CALCB 1.610 HSPA2* 1.666 NCRNA00153 1.552 TRPM8*† 1.601
CAPN2* 1.930 IGSF21* 2.067 NKX3-l*† 2.209 TSPAN33* 1.571
CDC2L2 1.608 JHDM1D 1.621 NOV* 1.844 UHMK1 1.764
CDK6 1.575 KCNK13* 2.066 NRK* 1.761 ULK2* 1.841
CHML 1.553 KCNK17 1.698 NUMBL* 1.902 VWA3A 1.571
COL16A1* 2.017 KLK3*† 3.084 OAZ2* 1.700 WIZ 1.627
CPEB2* 1.899 KLK4* 1.802 ODF3L2* 1.650 YPEL1* 2.116
CPT1C 1.604 KRT126P* 2.348 PALMD* 2.252 ZFX* 1.717
CUEDC1 1.774 LEPROT 1.831 PCDH20 1.969 ZNF264 1.553
CYP1B1 4.321 LOC100008589* 2.206 PIGL* 1.671 ZNF30* 1.577
DDIT4L* 3.243 LOC100129674 1.586 PM20D1 1.555 ZNF350 1.751
DIP2C* 1.684 LOC100130123* 1.893 PNPLA7* 1.627 ZNF414 1.899
DIS3L2 1.696 LOC100132394* 1.700 PP8961* 1.554 ZPLD1* 3.579
EDN1* 1.575 LOC100132564* 1.894 PPFIBP2* 2.087 B3Gn-T6* 0.494
EMP1* 1.760 LOC100133099 1.585 PPP1R3E* 1.563 CAMK1G 0.423
ENDOD1*† 2.467 LOC100133565* 2.217 PRICKLE1* 1.840 CGA 0.476
EPR1* 2.130 LOC145837* 1.680 PTPRR* 1.750 FANCB 0.445
ETS2* 1.998 LOC388681 1.677 PXK* 1.880 LOC100130775* 0.473
FAM129A* 1.576 LOC389286* 2.196 REPS2* 1.807 LOC347376 0.495
FAM134B* 2.035 LOC389901 1.566 RHOU 1.584 LOC440063 0.445
FAM46B* 1.688 LOC400214 1.552 RNF144A 1.563 MALL 0.495
FKBP5*† 1.640 LOC440122 1.617 SASH1* 1.560 TTC7B 0.477
*
co-regulated by DHT.
†
reported bona fide AR target gene.
Extended Data Table 3
Concentrations of Abi and its metabolites in a phase II clinical trial (NCT01393730).
Patient #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 #13 #14 #15 #16
Abi
cycle 3 439.46 64.74 210.65 447.29 80.78 195.53 117.58 79.58 135.63 200.93 190.73 320.19 66.11 177.31 131.86 205.48
cycle 4 1049.04 136.18 95.97 400.55 1399.54 288.80 214.26 207.19 148.05 393.35 219.20 569.72 173.93 203.84 178.06 289.94
cycle 7 1767.26 130.53 268.79 883.07 112.89 174.05 310.03 127.05 204.86 52.92 220.11 184.44 69.55 215.29 59.88 112.91
D4A
cycle 3 14.83 2.78 11.80 8.89 7.24 12.32 17.23 4.01 10.62 19.11 4.95 11.78 5.23 10.79 11.83 5.91
cycle 4 34.24 8.83 7.75 13.86 34.49 28.84 23.70 13.01 11.01 16.71 11.91 32.84 12.35 13.09 17.91 10.73
cycle 7 69.00 8.32 13.64 36.14 15.61 18.63 17.47 7.96 15.60 4.98 10.89 11.01 7.04 32.40 10.64 6.71
3-keto-5α-Abi
cycle 3 44.53 13.29 26.07 16.96 17.46 23.66 22.70 19.74 29.27 38.73 25.28 34.24 21.78 27.32 14.79 36.98
cycle 4 1.73 4.28 1.78 0.80 3.53 1.53 2.89 0.94 2.04 1.95 0.91 1.64 8.36 3.44 8.44 2.80
cycle 7 4.34 0.49 0.71 8.97 9.43 0.81 1.41 0.61 13.65 0.56 0.86 0.80 4.86 11.30 6.95 5.05
3α-0H-5α-Abi
cycle 3 15.81 4.45 4.04 3.80 4.53 5.65 4.12 4.86 8.80 9.57 5.56 8.82 5.52 6.16 2.69 3.27
cycle 4 0.22 0.01 0.18 0.14 0.77 0.35 0.53 0.16 0.52 0.51 0.08 0.01 1.85 0.48 1.91 0.28
cycle 7 0.84 0.00 0.00 2.45 1.35 0.05 0.00 0.00 2.81 0.08 0.00 0.12 0.98 1.77 1.92 0.49
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Patient #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 #13 #14 #15 #16
3β-0H-5α-Abi
cycle 3 5.15 1.31 2.31 2.26 3.25 2.00 1.21 1.63 2.75 3.43 1.55 2.87 2.54 5.81 3.89 1.06
cycle 4 0.31 0.03 0.60 0.21 2.16 0.09 0.31 0.06 0.32 0.20 0.09 0.17 1.17 1.93 3.83 0.16
cycle 7 0.59 0.01 0.13 4.04 2.32 0.04 0.17 0.07 3.22 0.05 0.12 0.12 0.50 5.59 2.69 0.31
3-keto-5β-Abi
cycle 3 15.63 6.24 93.39 31.14 55.55 12.21 39.43 12.83 52.75 24.97 23.05 25.00 18.55 57.78 78.37 73.90
cycle 4 53.05 20.41 41.95 43.95 65.31 24.55 51.38 58.97 24.22 63.34 26.42 36.53 28.47 60.61 73.60 127.48
cycle 7 141.23 17.17 42.09 75.30 101.40 25.41 24.44 24.65 47.59 20.24 34.29 18.47 29.70 205.11 56.29 102.62
3α-0H-5β-Abi
cycle 3 41.95 14.63 86.05 44.46 70.25 19.57 37.12 21.94 86.71 31.06 31.93 42.80 33.90 98.26 76.44 28.59
cycle 4 42.31 36.79 55.14 27.67 34.26 34.66 70.21 53.53 75.32 44.13 31.55 76.59 42.91 39.17 68.02 36.96
cycle 7 110.85 29.24 63.35 99.70 48.28 35.00 37.37 38.95 57.38 24.67 46.16 34.37 33.17 142.07 68.89 37.41
3β-0H-5β-Abi
cycle 3 35.68 18.41 121.85 96.16 129.09 23.92 33.38 33.95 103.67 59.47 41.23 65.71 31.22 216.92 127.26 48.69
cycle 4 36.33 40.71 115.43 54.54 50.89 35.06 72.74 78.52 82.78 77.29 35.08 83.37 39.21 125.80 114.74 71.33
cycle 7 95.93 26.97 80.34 180.42 114.67 40.48 41.48 52.28 73.76 40.39 51.22 47.96 42.08 387.83 106.73 82.47
Supplementary Material
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Figure 1. 
Genesis of 5α- and 5β-reduced Abi metabolites in patients treated with Abi acetate. a, 
Abiraterone metabolism by steroidogenic enzymes. Above, In a pathway of androgen 
metabolism, DHEA is converted by 3βHSD to Δ4-androstenedione (AD), which is 5α-
reduced to 5α-androstanedione (5α-dione), which is in turn 3-keto-reduced to androsterone. 
Below, Structurally analogous conversion of abiraterone to D4A enables 5α- and 5β-
reduction of D4A at carbon 5 (red arrow), yielding 6 additional Abi metabolites. Dotted 
arrows indicate uncertainty of direct conversion between 3α- and 3β-isomers (versus 
indirectly by way of the 3-keto intermediate). b, Interconversion of Abi metabolites in the 
LAPC4 prostate cancer cell line. Cells were treated with Abi or the indicated metabolite (0.1 
μM) for 48 hours and each of the indicated metabolites was detected by liquid 
chromatography-mass spectrometry (LC-MS/MS) in triplicate. Errors bars represent the SD. 
c, In vivo Abi metabolism in mice. Treatment with Abi (n = 5 mice) or D4A (n = 5 mice) 
results in detection of all 6 5-reduced metabolites. Treatment with any of the 3 5α-reduced 
Abi metabolites (n = 4 mice for each compound) results in detection of the 2 other 5α-
reduced metabolites, demonstrating interconversion. d, Abi metabolites in sera of 12 patients 
with prostate cancer treated with Abi acetate. Metabolites were measured by LC-MS/MS.
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Figure 2. 
Effects of 5α-reduced Abi metabolites on the androgen pathway and tumor progression. a, 
Potent CYP17A1 inhibition activity attributable to Abi and D4A is attenuated with 
conversion to 5α-Abi and 3α-OH-5α-Abi. 293 cells overexpressing CYP17A1 were treated 
with [3H]-pregnenolone and conversion to DHEA was assessed in the presence of the 
indicated drugs. b, 5α-reduction of D4A causes loss of 3βHSD inhibitory activity. LNCaP 
cells were treated with [3H]-DHEA and the indicated drugs for 48 hours, and metabolic flux 
to AD was assessed. c, 5α-Abi and 3α-OH-5α-Abi lose SRD5A inhibition activity 
attributable to D4A. LAPC4 cells were treated with [3H]-AD and the indicated drugs, and 
flux to 5α-dione was assessed after 24 hours of incubation. **, p < 0.01. d, 5α-Abi and D4A 
comparably bind to AR. LNCaP and LAPC4 express the mutated AR and wild-type AR, 
respectively, and were incubated with [3H]-R1881 and the indicated compounds for 30 min. 
Intracellular radioactivity was normalized to protein concentration. e and f, 5α-Abi 
stimulates androgen-responsive gene expression in LAPC4 and LNCaP. Delayed and more 
modest PSA expression is stimulated with 3α-OH-5α-Abi. g, Dose-dependent stimulation 
of PSA expression by 5α-Abi in LAPC4. h, Treatment with 5α-Abi (n=10 mice) but not 3α-
OH-5α-Abi (n=9 mice) hastens VCaP CRPC xenograft growth compared with control (n=9 
mice) in orchiectomized mice. Treatment with the indicated compounds began when CRPC 
tumors reached 100 mm3 and progression-free survival was assessed as the time at which 
there was > 30% growth for 2 sequential measurements. The significance of the difference 
between treatment groups was assessed with the log rank test. ** p < 0.01 for the difference 
between 5α-Abi and Ctrl; *, p<0.05. i, 5β-reduced Abi metabolites do not stimulate PSA 
expression. Expression is normalized to RPLPO and vehicle expression in EG and I. Error 
bars represent the SD in A–G and I. All experiments in A–G and I were performed at least 3 
times.
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Figure 3. 
Long-term exposure to Abi and D4A leads to an increase in SRD5A expression and 
enzymatic activity and an increase in conversion from D4A to 5α-reduced Abi metabolites. 
a, Experimental schema. VCaP cells were cultured with DHEA (100 nM) alone, or with the 
indicated concentration of Abi or D4A continuously for 6 months. LNCaP cells were treated 
under similar conditions (LN1, LN3 and LN5 = VCaP1, VCaP3 and VCaP5 treatment, 
respectively). Treatment with Abi or D4A induces an increase in SRD5A enzyme activity 
and increased conversion of D4A to 5α-Abi metabolites in b, VCaP and c, LNCaP. Cells 
were treated with [3H]-AD, [3H]-T, or D4A for 24 or 48 hours, and conversion to 5α-
reduced metabolites was assessed by HPLC. SRD5A1 protein expression is increased with 
Abi and D4A treatment in d, VCaP and e, LNCaP. b and c were performed in triplicate with 
error bars representing the SD. All experiments were performed at least 3 times.
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Figure 4. 
In patients treated with Abi acetate, SRD5A inhibition significantly increases serum D4A 
and specifically and significantly depletes all 3 5α-Abi metabolites in serum. a, Clinical trial 
schema. Blood was collected for Abi metabolites after 2 months of treatment with Abi 
acetate + prednisone (start cycle 3), and again after 1 and 4 months (start cycles 4 and 7) of 
addition of treatment with dutasteride. Serum concentrations of b, Abi, c, D4A, d, all 3 5α-
reduced Abi metabolites, e, all 3 5β-reduced Abi metabolites, in sera. The mean Abi and Abi 
metabolite concentrations at each of the 3 time points in the clinical trial are indicated.
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